| Record ID | harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:258991804:1704 |
| Source | harvard_bibliographic_metadata |
| Download Link | /show-records/harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:258991804:1704?format=raw |
LEADER: 01704cam a2200349 a 4500
001 013226042-5
005 20120706194640.0
008 120601r20122005dcua b f000 0 eng d
035 0 $aocn794595960
040 $aVVC$cVVC$dVVC$dMH-L
043 $an-us---
050 4 $aKF26$b.F5 2005x
050 4 $aKF26$b.F5 2012
086 0 $aY 4.F 49:S.HRG.108-791
110 1 $aUnited States.$bCongress.$bSenate.$bCommittee on Finance.
245 10 $aFDA, Merck, and Vioxx, putting patient safety first? :$bhearing before the Committee on Finance, United States Senate, One Hundred Eighth Congress, second session, November 18, 2004.
260 $aBuffalo, N.Y. :$bWilliam S. Hein.,$c2012.
300 $aiv, 971 p. :$bill. ;$c26 cm.
490 1 $aS. hrg. ;$v108-791
490 1 $aHein's electronic documents reprint series ;$vtitle 33
500 $aReprint of a congressional hearing. Original version withdrawn in 2006 by the U.S. Government Printing Office before distribution to depository libraries.
530 $aStatements of committee chairs and testimony of expert witnesses also available via Internet from the GPO permanent archive. Address as of 10/25/06: http://permanent.access.gpo.gov/lps75299/merckvioxx.pdf; current access available via PURL.
504 $aIncludes bibliographical references.
650 0 $aDrugs$xLaw and legislation$zUnited States.
650 0 $aRofecoxib.
610 20 $aMerck & Co.$xCorrupt practices.
650 0 $aDrug monitoring$zUnited States.
650 0 $aDrugs$zUnited States$xTesting.
810 1 $aUnited States.$bCongress.$bSenate.$tS. hrg ;$v108-791.
830 0 $aHein's electronic documents reprint series ;$vtitle 33.
988 $a20120605
906 $0OCLC